The lack of cytomegalovirus-specific cellular immune response may contribute to the onset of organ infection and disease in lung transplant recipients. by Costa, C. et al.
  
 
 
This is an author version of the contribution published on: 
Questa è la versione dell’autore dell’opera: 
 
Costa C, Saldan A, Sinesi F, Sidoti F, Balloco C, Simeone S, Piceghello A, Mantovani S, Di Nauta A, 
Solidoro P, Cavallo R, International Journal of Immunopathology and Pharmacology, Volume 25, 
No 4, Editor Biolife, 2012, pagg.1003-1009 
The definitive version is available at: 
La versione definitiva è disponibile alla URL: 
http://www.biolifesas.org/contentsrosso.htm 
The lack of cytomegalovirus-specific cellular immune response may contribute to 
the onset of organ infection and disease in lung transplant recipients. 
 
1
C Costa, 
2
A Saldan, 
1
F Sinesi, 
1
F Sidoti, 
1
C Balloco, 
1
S Simeone, 
1
A Piceghello, 
1
S 
Mantovani, 
1
A Di Nauta, 
3
P Solidoro, 
1
R Cavallo. 
 
1
Virology Unit, Hospital Città della Salute e delle Scienza di Torino - San Giovanni 
Battista Hospital, Turin, Italy. 
2
Department of Histology, Microbiology and Medical 
Biotechnology – Padua General Hospital, Padua School of Medicine, Padua, Italy. 
3
Division of Pneumology, Hospital Città della Salute e delle Scienza di Torino - San 
Giovanni Battista Hospital, Turin,  Italy. 
 
 
 
Corresponding author:  
Cristina Costa, MD, PhD 
Virology Unit 
University Hospital San Giovanni Battista di Torino 
Via Santena 9 – 10126 Turin – Italy. 
Phone:  +39(11)6705630  
Fax: +39(11)6705648  
e-mail: cristina.costa@unito.it, ccosta2@molinette.piemonte.it 
 
Conflict of interest: none. 
Summary 
Cellular immune response has been demonstrated to play a role in the control of human 
cytomegalovirus (HCMV) replication in organ transplant recipients. Herein, HCMV-
specific T-cell response and association to the onset of organ infection/disease were 
prospectively evaluated by EliSPOT assay in a population of 46 lung transplant (LT) 
recipients at months 1, 3, 6, 9 and 12 posttransplantation. According to our centre’s 
practice, a combined prolonged antiviral prophylaxis (HCMV-IG for 12 months and 
ganciclovir or valganciclovir for 3 weeks from postoperative day 21) was given to all 
LT recipients. HCMV-DNA was concomitantly detected on bronchoalveolar lavage 
(BAL) and whole blood by real-time PCR. Approximately one third of patients resulted 
HCMV persistently non-responder; the rate of HCMV infection, as evaluated by 
HCMV-DNA positivity, tended to be higher in non-responders. Mean viral load on 
BAL was significantly higher in non-responders vs other patients (p <0.001). Temporal 
profile of infections appeared related to the HCMV responder status with a shorter time 
to onset of infection post-transplantation and a longer duration in non-responders. The 
occurrence of organ disease (i.e. pneumonia) tended to be higher in non-responders, 
with poor prognosis, as death occurred in one of three non-responder patients that 
developed HCMV pneumonia.  
The lack of HCMV-specific cellular response can contribute to the onset of organ 
infection and disease also in patients in which antiviral prophylaxis was adopted; this 
could be due to the potential occurrence of incomplete control of replication in lungs or 
a delayed priming of T-cell reconstitution.  
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Introduction 
Human cytomegalovirus (HCMV) is a ubiquitous β-herpes virus that, following primary 
infection, establishes latency in host tissues and may reactivate in immunocompromised 
conditions. In solid organ transplant recipients, the incidence of HCMV infection and 
disease is variable according to the transplanted organ and is particularly high in lung 
transplantation (LT), being approximately 40% for both (1). Lung is a HCMV latency 
site and in LT, viral reactivation has been associated to direct (i.e. organ and systemic 
infection/disease) and indirect effects (including acute rejection and chronic allograft 
dysfunction), thus limiting the success of transplantation. Two strategies are usually 
adopted in the clinical management of transplant recipients: anti-viral prophylaxis and 
pre-emptive therapy, consisting in the administration of antiviral agents after reaching a 
predetermined cutoff in blood, but prior to the development of clinical symptoms. 
Therefore, virological monitoring is fundamental in the clinical decision-making 
process and, in LT, it is usually performed by evaluation of HCMV-DNA on 
bronchoalveolar lavage (BAL) and whole blood specimens. Beside this, in recent years, 
viro-immunological monitoring with evaluation of specific T-cell response has been 
introduced. Cell-mediated immune response has been demonstrated to play a role in the 
control of HCMV replication in the transplant setting, as early recovery following 
transplantation seems able to prevent and reduce the duration of infection, thus avoiding 
the onset of overt disease or recurrence, while a delayed/reduced response should 
represent the pathogenic basis for recurrent infections that may become symptomatic in 
the absence of treatment (2-4). Several assays are available for the evaluation of 
HCMV-specific cellular immune response, including intracellular cytokine staining, 
QuantiFERON®- CMV, EliSPOT assay, and MHC multimer staining, all of which 
present advantages and limitations, as reported by the International Consensus 
Guidelines on the Management of Cytomegalovirus in solid organ transplantation (5). 
Among these, EliSPOT is an interferon (IFN)-γ-releasing assay (IGRA), that 
enumerates IFN-γ-secreting T-cells in response to stimulation with HCMV peptides and 
seems to represent a robust and reproducible tool for monitoring T-cell activity ex-vivo 
(6). Current evidence suggests that immunological monitoring tests can predict the risk 
of HCMV viremia and disease in both the post-prophylaxis and pre-emptive setting (5); 
while less is known about the impact of viro-immunological monitoring in the 
prophylaxis period. Anti-viral prophylaxis is effective in inhibiting viral replication, 
however is also associated to a delayed priming of T-cell immune reconstitution and 
higher incidence of late-onset HCMV disease. Herein we evaluated the clinical impact 
of viro-immunological monitoring of HCMV in a population of LT recipients having 
received anti-viral prophylaxis. 
 
Materials and methods 
Patient population included 46 lung transplant recipients followed-up in the first year 
post-transplantation; the main features of study population are reported in Table I. 
According to our centre’s practice, LT recipients were submitted to surveillance visits at 
1, 3, 6, 9, and 12 months; further visits are performed at 18 and 24 months post-
transplantation and then annually, as well as in the presence of clinical signs and/or 
symptoms and/or rejection (7). At each visit whole blood and BAL were collected, 
accounting for a total number of 184 combined samples. Further BAL and whole blood 
specimens were collected within two weeks for checking-up a previous positivity; in 
these cases, no evaluation of cellular immune response was made. Long-term 
immunosuppression was maintained with three drugs: tacrolimus or cyclosporine A (in 
patients with cystic fibrosis as underlying disease), mycophenolate mofetil and 
prednisone (to be tapered at low dosage or discontinued). According to our centre’s 
practice, all LT recipients received a universal and combined anti-viral prophylaxis for 
HCMV consisting in the administration of ganciclovir (5 mg/kg twice daily) or 
valganciclovir (450 mg twice daily) from day 21 for 3 weeks associated to HCMV-IG 
(Cytotect Biotest) at days 1, 4, 8, 15, and 30 (1.5 ml/kg body weight) and every month 
up to 1 year post-transplantation (1 ml/kg body weight), irrespective of HCMV 
serostatus (8). Ganciclovir or valganciclovir were further administered based on clinical 
judgement and/or in case of HCMV-DNA load on BAL higher than 10
5
 copies/ml 
and/or in case of HCMV-DNA load on whole blood higher than 10
5
 copies/ml. As 
previously described (9), HCMV infection was defined as laboratory evidence of viral 
reactivation in the absence of clinical signs and/or symptoms;  HCMV syndrome as 
viral detection in the presence of fever, leukopenia, thrombocytopenia, increased 
hepatic transaminases, malaise; and localized (organ) disease as viral detection in organ 
tissues or local secretions in association or not with viral detection in blood and 
symptoms/signs of organ involvement. Viral load was quantified by a commercially 
available real-time TaqMan PCR assay, as previously described (limit of detection, 
1800 copies/ml BAL and 2400 copies/ml whole blood)(8). The EliSPOT assay was 
optimized and performed, as described elsewhere (7). Briefly, automated separation of 
total CD3+ cells was performed with the RoboSep® cell separator (StemCell 
Technologies, Vancouver, Canada) using the EasySep negative selection protocol, 
following the manufacturer’s instruction. An aliquot of 2 x 105 cells were used for 
EliSPOT assay (EliSpot Interferon-γ Basis Kit; AID, Strassberg, Germany) and 
incubated on anti-IFN-γ coated wells together with HCMV-specific peptide mix 
(including pp65 and IE-1 peptides [Nanogen Advanced Diagnostics, Milan, Italy]) for 
20 hours in a CO2 incubator; antigen-induced IFN-γ production was visualized by an 
enzyme-labelled detection antibody, with coloured spots representing one cell secreting 
IFN-γ. Results were analyzed using a computer-assisted system (AID EliSpot Reader 
System, AID). For negative and positive controls, cells incubated with RPMI -1640 
medium (Sigma-Aldrich, St. Louis, MO, USA) alone and with phytohemagglutinin 
mitogen were used, respectively. Specific immune response was evaluated as previously 
described (4); in particular, a number of spot forming units <5/200,000 cells as no 
response (non-responders), 5-20 as a weak response, 20-100 as a good response, and 
>100 as a very good response (responders). Temporal profile of reconstitution of 
cellular response post-transplantation  (i.e. early responder in the presence of a 
responder status at first evaluation at day 30 and late responder in its absence) was also 
evaluated. Data are expressed as raw numbers, percentages, and means, as appropriate. 
For statistical analysis, the chi square, the Fisher’s exact and ANOVA tests was applied, 
as appropriate, using a commercially available software (MedCalc version 9.2.1.0, 
Mariakerke, Belgium). A p-value <0.05 was considered statistically significant. 
   
Results 
Results are summarized in Table II. Overall, 27 patients (58.7%) displayed an  early 
responder status (good or very good response in all the cases), five (10.9%) were late or 
transiently (depending on the episode) responders (weak or good response), and 14 
(30.4%) persistently non-responders (including the three individuals with D-/R- 
serological matching, as expected). An episode of  HCMV infection (as evidenced by 
positivity on whole blood and/or BAL specimens) occurred within the first year post-
transplantation in 50% of study population (23/46 patients); in particular, in 13 of 27 
(48.1%) early responders, two of five (40%) late or transiently responders, and eight of 
14 (57.1%) non-responders. Repeated episodes of HCMV infection were detected in 
three of non-responder recipients and I no patient from other groups. Primary HCMV 
infection occurred in the D+/R- patient; this single episode of infection induced the 
development of a responder status. Although the rate of infections tended to be higher in 
non-responders, this does not reach the statistical significance. Mean viral load on BAL 
was significantly higher in non-responders vs other groups (1.4 x 10
5
 ± 2.4 x 10
4
 
copies/ml BAL vs 7.9 x 10
3
 ± 1.4 x 10
3
 and 2.4 x 10
3
 in early responders and late or 
transiently non-responders, respectively)(p <0.001). No patient presented viral load on 
whole blood higher than 10
4
 copies/ml and values were highly overlapping in the 
different groups. Interestingly, in transiently non-responder individuals the episode of 
infection coincided with the occurrence of non-responsiveness. Temporal profile of 
infection appeared related to HCMV-responder status of the patient, with a shorter time 
to onset of infection post-transplantation in non-responders (mean days post-
transplantation: 68 in non-responders, 109 in late or transiently non-responders and 204 
in early responders) and a longer duration of infection (>14 days to HCMV-DNA 
negativity on BAL in non-responders and late or transiently non-responders vs <14 in 
early responders). Similar data regarding onset of infection and duration of infection 
were found for HCMV detection of whole blood specimens. 
The occurrence of HCMV organ disease (HCMV pneumonia confirmed at 
histopathology and immunohistochemistry [10]) tended to be higher (p = not 
significant) in non-responders: in particular, three of 14 (21.3%) patients vs two of 27 
(7.4%) in early responders and no cases in late or transiently non-responders. The 
outcome was different according to HCMV immune response status: in fact, while 
pneumonia had a favourable outcome in responders (resolution following anti-viral 
administration in both cases), death for HCMV pneumonia occurred in one of three 
non-responders, despite of anti-viral treatment (mortality, 33.3%). No patient developed 
HCMV systemic syndrome. The kinetics of HCMV-specific T-cell reconstitution and 
HCMV replication in lung in different types of patients, that were representative of 
most common courses, are reported in Figure 1. 
 
Discussion 
HCMV is among the most important viral pathogens affecting the outcome of LT 
recipients, with direct effects being responsible for significant morbidity and mortality 
and several indirect effects with detrimental consequences on survival. Given the 
potentially severe impact of HCMV in LT, physicians must adopt effective strategies to 
prevent the onset of HCMV disease. Specific cellular immune response plays a crucial 
role in containing viral replication, thus potentially representing a determinant factor in 
the outcome of LT and a useful tool for the clinical decision-making process. This could 
be accomplished by evaluating the need to administer antiviral agents in relation to the 
responder status, as well as could represent the basis for the development of studies on 
the use of adoptive immunotherapy with generated HCMV T cells. Some considerations 
can be made based on the results of the present study. The onset of HCMV infection in 
LT recipients is quite common during the first year post-transplantation despite the 
adoption of a prolonged and universal prophylactic strategy, although the incidence of 
infection appears to be lower than that reported by other studies adopting pre-emptive 
treatment (11). Considering specific cellular immune response, approximately one third 
of our population resulted persistently non-responder to HCMV up to 1 year post-
transplantation. Interestingly, a small subgroup of patients displayed a delayed pattern 
of immune reconstitution (at >30 days, although all of them within 3 months 
posttransplantation) or a transient phase of non-responsiveness within a responder 
pattern. This subgroup evidenced no increased rate of infection as well as no need to 
treat; the only difference in comparison to early responder patients appeared to be a 
tendency to an earlier onset of infection posttranplantation (Table II) and/or the 
occurrence of infection in concomitance with the non-responsiveness phase, although 
viral load on BAL was low and HCMV-DNAemia was negative in all the cases. The 
lack of a specific cellular immune response seems to be associated to a tendency to a 
higher rate and a longer duration of infection, thus confirming that incomplete control 
of viral replication in lungs may occur during prophylaxis. The degree of local viral 
replication appears to be significantly higher in the absence of  an efficient immune 
control, as evidenced by the evaluation of viral load on BAL from responder and non-
responder patients and the lack of significant association to viral detection and load on 
whole blood. The occurrence of viral replication  may lead to the onset of organ disease, 
in the absence of HCMV-specific cellular immune response, potentially leading to death 
as evidenced in the patient who developed HCMV-pneumonia and eventually died, in 
contrast to the favourable resolution of infectious episode in responder patients. The 
small size of our study population certainly represents a limit for statistical analysis, 
although this is due to the activity volume of lung transplantation; the collection of 
more data in the subsequent years will allow to further support these observation. Few 
studies have investigated HCMV-specific cellular response in LT. Sester and coll. found 
that specific T-cell levels were significantly lower in LT in comparison to controls and 
showed a significant correlation with the frequency of infectious episodes (12). 
Similarly, Gerna and coll. found that HCMV-specific cellular response was associated 
to resolution of lung infection (11). At present, evaluation of T-cell immune response 
(viro-immunological monitoring) may complement virological monitoring and help to 
identify lung transplant recipients at risk of developing organ infection/disease. Further 
studies will allow to support these conclusions and to investigate the potential 
implications in terms of indirect effects of  viral infection/disease, such as onset of acute 
or chronic rejection, particularly at >1 year post-transplantation when antiviral 
prophylaxis is discontinued and it is possible the development of late-onset HCMV-
disease. The impact of different immunosuppressive protocols in the context of LT 
remains to be investigated, in that it is likely that tacrolimus levels play a role in 
determining the degree of suppression of HCMV-specific cellular immune response, as 
demonstrated for polyomavirus BK in renal transplantation (13), possibly due to its 
action on T cell proliferation. An interesting issue that should be further investigated is 
the role played by the underlying pathological background. Recent studies have 
suggested an inflammatory/autoimmune T cell-mediated component in the pathogenesis 
of chronic obstructive pulmonary disease/emphysema (14,15). In our population no 
significant differences of responder status was found according to the underlying 
disease that lead to transplantation, although the limited size of population should be 
taken into account.  
In conclusion, the lack of HCMV-specific cellular response can contribute to the onset 
of organ infection and disease also in patients in which antiviral prophylaxis has been 
adopted; this could be due to the potential occurrence of incomplete control of 
replication in lungs or a delayed priming of T-cell reconstitution.  
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Table I. Main features of study population. SD, standard deviation; COPD, chronic 
obstructive pulmonary disease. 
 
Features 
Patients 
N = 46 
Mean age (years +/- SD) 48.9 +/- 18.5 
Gender (M/F) 25/21 
Underlying disease 
   Cystic fibrosis 
   Idiopathic pulmonary fibrosis 
   COPD/emphysema 
   Alpha-1-antitrypsin deficiency 
   Bronchiectasis 
   Histiocytosis X 
   Hyaline membrane disease 
   Extrinsic allergic alveolitis 
   Progressive systemic sclerosis 
 
22 (47.8%) 
4 (8.7%) 
13 (28.2%) 
1 (2.2%) 
2 (4.3%) 
1 (2.2%) 
1 (2.2%) 
1 (2.2%) 
1 (2.2%) 
Type of lung transplant 
   Single 
   Double 
  Retransplantation 
 
16 (34.8%) 
28 (60.9%) 
2 (4.3%) 
HCMV Serostatus (D/R) 
   D+/R+ 
   D+/R- 
   D-/R- 
   D-/R+   
34 (73.9%) 
1 (2.2%) 
3 (6.5%) 
8 (17.4%) 
 
Table II. Viro-immunological monitoring of HCMV-specific cellular response in 
study population. N, number; BAL, bronchoalveolar lavage; SD, standard deviation; 
tx, transplantation; n.s., not significant. Viral load is expressed as genome copies/ml 
BAL. *Occurrence of HCMV pneumonia confirmed by histopathological analysis 
and immunohistochemistry. Early responders: reconstitution of cellular immune 
response within 30 days post-transplantation; late responders: reconstitution of 
cellular immune response at >30 days post-transplantation. 
 
Total 
N = 46 
Early responders 
N = 27 (58.7%) 
Late or transiently 
responders 
N = 5 (10.9%) 
Non-responders 
N = 14 (30.4%) 
P 
Infections within 1
st
 year 
post-tx 
13 (48.1%) 2 (40.0%) 8 (57.1%) n.s. 
Viral load on BAL  (mean 
± SD) 
7.9x10
3
 ± 1.4x10
3
 2.4x10
3
 1.4x10
5
±2.4x10
4
 <0.001 
Onset of infection (mean 
days post-tx ± SD) 
204 ± 51 109 ± 43 68 ± 29 n.s. 
Duration of infection (days 
to negativity) 
<14 >14 >14 - 
HCMV pneumonia* 2 (7.4%) 0 3 (21.3%) n.s. 
Antiviral administration 4 (14.8%) 0 6 (42.9%) n.s. 
Outcome Resolution - 1 death (7.1%) - 
 
 
Figure 1. Kinetics of HCMV-specific T-cell reconstitution (continue line) and HCMV 
replication in lung (dotted line) in the first year post-transplantation in different types of 
patients. A, responder who did not develop infection; B, responder who developed 
infection with resolution following antiviral treatment; C; transiently non-responder 
who developed infection in coincidence with non-responsiveness period; D, non-
responder who developed HCMV-pneumonia and eventually died at approximately 9 
months post-transplantation. SFU, spot forming units, corresponding to the number of 
IFN-γ secreting cells/200,000 peripheral blood mononuclear cells; BAL, 
bronchoalveolar lavage; tx, transplantation. Viral load is expressed as copies/ml BAL. 
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